Pregabalin, Serum or Plasma
Use
This test is used to optimize drug therapy and monitor patient adherence for individuals taking Pregabalin. It helps ensure appropriate therapeutic levels and avoid potential adverse effects. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Therapeutic and toxic ranges for Pregabalin are not well established, but a proposed dose-related range is 2-10 ug/mL. Monitoring is necessary as adverse effects may include peripheral edema, allergic reactions, dizziness, and somnolence.
Special Instructions
Separate from cells as soon as possible or within 2 hours of collection. Transfer 1 mL of serum or plasma to an ARUP Standard Transport Tube. Minimum volume is 0.2 mL. Collect specimen as a pre-dose (trough) draw at steady-state concentration in plain red, lavender (K2EDTA/K3EDTA), or pink (K2EDTA) tubes.
Limitations
The therapeutic and toxic ranges for Pregabalin are not well established. Results must be interpreted within the clinical context of the patient, considering potential factors that may influence drug levels such as compliance, drug interactions, and individual variations in metabolism and excretion. The test should not be the sole indicator for adjusting therapy without considering clinical findings and other diagnostics.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 47414-8
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect pre-dose (trough) at steady-state in plain red, lavender (K2EDTA or K3EDTA), or pink (K2EDTA) tubes. Separate from cells within 2 hours.
Causes for Rejection
Citrated plasma.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 month |
| Refrigerated | 1 month |
| Frozen | 2 months |